Is the PRESENT study a present for people with breast cancer?
A small biopharmaceutical company (Galena Biopharma) passed a major milestone today in gaining the 70th qualifying disease free survival patient in a phase three FDA study. What this means is that an interim analysis (early look at results) will be undertaken.
The benefit for potentially millions of breast cancer patients is that they can receive a vaccine (NeuVax) if the experimental vaccine reaches FDA approval.
More to follow as usual but the promise of PRESENT can’t be underestimated.